Home > Vaccine

Moderna’s Omicron-focused Vaccine Better than Original COVID-19 Vaccine

Moderna Inc. claimed that its Omicron-focused COVID-19 vaccines had improved immune responses against BA.4 and BA.5 sub-variants of Omicron, found Moderna’s latest study. Data suggests that in adults who had been vaccinated and received booster shots, both of Moderna’s Omicron-focused vaccines, including mRNA-1273.214 and mRNA-1273.222, has produced high antibody response

Read More

Researchers from IIT Jodhpur Discovered COVID-19 RNA Variations and Implications

Using cutting-edge genome sequencing techniques, researchers at the Indian Institute of Technology (IIT), Jodhpur, have discovered variants in the COVID-19 virus’s RNA, according to officials. The fixation of these intra-host variations and mutations that results in variants have both been researched by experts. The journal “Nucleic Acid Research” has published

Read More

Covaxin’s low offtake, 50 million doses scheduled to expire in early 2023

Due to low demand, about 50 million doses of Covaxin, a COVID-19 vaccine produced by Bharat Biotech, are expected to run out early in the following year. Despite having planned for production to achieve a yearly capacity of 1 billion doses by the end of 2021, Bharat Biotech, halted manufacturing the

Read More

US FDA authorized Updated COVID-19 Booster Shots for Children Above 5 years

The US Food and Drug Administration (FDA) has authorized updated COVID-19 booster vaccine shots developed by Moderna and Pfizer/BioNTech, for children aged five years and above to enhance protection against the COVID-19 virus. The US FDA has updated the emergency use authorizations for the Modern COVID-19 vaccine, and the Pfizer/BioNTech COVID-19

Read More

Pfizer/BioNTech Seeks US FDA Approval for New COVID-19 Boosters for Children

Pfizer and its German partner BioNTech are asking the US Food and Drug Administration (FDA) to approve the new COVID-19 booster vaccine shots targeting the Omicron variant for school-age children. Pfizer and BioNTech submitted an application for emergency use authorization of their BA.4 and BA.5 focused bivalent vaccines for children

Read More